Ignite Creation Date:
2024-05-05 @ 12:04 PM
Last Modification Date:
2024-10-26 @ 9:19 AM
Study NCT ID:
NCT00232596
Status:
COMPLETED
Last Update Posted:
2016-12-08
First Post:
2005-09-30
Brief Title:
Retigabine Adjunctive Therapy Efficacy and Safety Study for Partial Onset Refractory Seizures in Epilepsy
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Organization Data
Organization:
GlaxoSmithKline
Class:
INDUSTRY
Study ID:
VRX-RET-E22-301
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
GlaxoSmithKline
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Bausch Health Americas Inc | INDUSTRY |